{"id":4526,"date":"2026-11-02T17:27:02","date_gmt":"2026-11-02T14:27:02","guid":{"rendered":"https:\/\/www.sonerduzguner.com\/?p=4526"},"modified":"2026-11-02T17:27:02","modified_gmt":"2026-11-02T14:27:02","slug":"bexsero-asisi-nedir","status":"publish","type":"post","link":"https:\/\/www.sonerduzguner.com\/en\/bexsero-asisi-nedir\/","title":{"rendered":"Bexsero A\u015f\u0131s\u0131 Nedir?"},"content":{"rendered":"
\n\t
\n\t\t
\n\t\t\t

Bexsero, meningokok B bakterisinin neden oldu\u011fu menenjit ve kan dola\u015f\u0131m\u0131 enfeksiyonlar\u0131na kar\u015f\u0131 korunmaya yard\u0131mc\u0131 olan bir a\u015f\u0131d\u0131r. G\u00fcnl\u00fck dilde \u201cmenenjit B a\u015f\u0131s\u0131\u201d olarak da an\u0131l\u0131r. Ancak menenjitin farkl\u0131 nedenleri vard\u0131r; Bexsero t\u00fcm menenjit t\u00fcrlerine kar\u015f\u0131 koruma sa\u011flamaz.<\/strong>[1,3]<\/p>\n\n

Bexsero a\u015f\u0131s\u0131<\/a>, 2 ayl\u0131ktan itibaren uygulanabilen, doz say\u0131s\u0131 ve uygulama aral\u0131klar\u0131 ilk dozun yap\u0131ld\u0131\u011f\u0131 ya\u015fa g\u00f6re de\u011fi\u015fen bir a\u015f\u0131d\u0131r. A\u015f\u0131 plan\u0131 olu\u015fturulurken ya\u015f, \u00f6nceki a\u015f\u0131 kay\u0131tlar\u0131 ve ki\u015fisel riskler birlikte de\u011ferlendirilir. Bu yaz\u0131da Bexsero\u2019nun hangi hastal\u0131klara kar\u015f\u0131 kullan\u0131ld\u0131\u011f\u0131n\u0131, a\u015f\u0131 takvimini ve doz \u015femas\u0131n\u0131, yan etkilerini ve a\u015f\u0131lama \u00f6ncesinde bilinmesi gerekenleri bulabilirsiniz.[1]<\/p>\n\n

<\/span>Meningokok B Nedir, Hangi Hastal\u0131klara Neden Olur?<\/span><\/h2>\n\n

Meningokok B, Neisseria meningitidis<\/em> bakterisinin bir grubudur. Beyin ve omurili\u011fi \u00e7evreleyen zarlar\u0131n iltihab\u0131 olan menenjite ve kan dola\u015f\u0131m\u0131 enfeksiyonlar\u0131na neden olabilir. Bu enfeksiyonlar ciddi seyredebilir ve sepsise yol a\u00e7abilir. A\u015f\u0131lama, bu hastal\u0131klardan korunmaya y\u00f6nelik bir \u00f6nlemdir; mevcut enfeksiyonun tedavisi de\u011fildir.[1,3]<\/p>\n\n

<\/span>Bexsero A\u015f\u0131s\u0131 Ne \u0130\u015fe Yarar, Nas\u0131l Etki Eder?<\/span><\/h2>\n\n

Bexsero, bakteriye ait bile\u015fenleri ba\u011f\u0131\u015f\u0131kl\u0131k sistemine tan\u0131tarak savunma yan\u0131t\u0131 olu\u015fmas\u0131n\u0131 sa\u011flar. Canl\u0131 meningokok bakterisi i\u00e7ermez; yani Bexsero canl\u0131 a\u015f\u0131 de\u011fildir.<\/strong> Korunma i\u00e7in ya\u015fa uygun a\u015f\u0131lama serisinin tamamlanmas\u0131 \u00f6nemlidir.[1,2]<\/p>\n\n

<\/span>Bexsero Kimlere Yap\u0131l\u0131r?<\/span><\/h2>\n\n

Bexsero bebeklerde, \u00e7ocuklarda, ergenlerde ve yeti\u015fkinlerde de\u011ferlendirilebilir. Bebeklerde menenjit B a\u015f\u0131s\u0131<\/a> 2 ayl\u0131ktan itibaren uygulanabilir. Bir ya\u015f grubunda kullan\u0131m\u0131n\u0131n onayl\u0131 olmas\u0131, o gruptaki herkes i\u00e7in ayn\u0131 a\u015f\u0131lama \u00f6nerisinin ge\u00e7erli oldu\u011fu anlam\u0131na gelmez. Uygulama karar\u0131 \u00fclkenin \u00f6nerileri ve ki\u015finin risk durumuyla birlikte verilir. \u00dcr\u00fcn bilgisinde 50 ya\u015f \u00fczerindeki yeti\u015fkinler i\u00e7in veri bulunmad\u0131\u011f\u0131 belirtilmektedir.[2]<\/p>\n\n

Randevu planlarken do\u011fum tarihini ve varsa \u00f6nceki meningokok a\u015f\u0131lar\u0131n\u0131n adlar\u0131n\u0131 payla\u015fman\u0131z yararl\u0131d\u0131r. B\u00f6ylece farkl\u0131 a\u015f\u0131lar ve tamamlanmam\u0131\u015f dozlar birlikte de\u011ferlendirilebilir.<\/p>\n\n

<\/span>Bexsero A\u015f\u0131s\u0131 Ka\u00e7 Doz Yap\u0131l\u0131r?<\/span><\/h2>\n\n

Bexsero a\u015f\u0131s\u0131n\u0131n ka\u00e7 doz yap\u0131laca\u011f\u0131 ve doz \u015femas\u0131 ilk doz s\u0131ras\u0131ndaki ya\u015fa g\u00f6re belirlenir. A\u015fa\u011f\u0131daki tablo, T\u00fcrkiye kullanma talimat\u0131 ve EMA \u00fcr\u00fcn bilgisindeki ba\u015flang\u0131\u00e7 \u015femalar\u0131n\u0131 \u00f6zetler. Uygulama \u00f6ncesinde g\u00fcncel yerel \u00fcr\u00fcn bilgisi ve a\u015f\u0131 kay\u0131tlar\u0131 kontrol edilir.[1,2]<\/p>\n\n

\n\n\n\n\n\n\n\n\n
\u0130lk dozdaki ya\u015f<\/th>\nBa\u015flang\u0131\u00e7 serisi ve en k\u0131sa aral\u0131k<\/th>\nHat\u0131rlatma dozu<\/th>\n<\/tr>\n<\/thead>\n
2\u20135 ay<\/td>\nEn az 1 ay arayla 3 doz veya en az 2 ay arayla 2 doz<\/td>\n12\u201315 ayl\u0131kken; ba\u015flang\u0131\u00e7 serisinin son dozundan en az 6 ay sonra<\/td>\n<\/tr>\n
6\u201311 ay<\/td>\nEn az 2 ay arayla 2 doz<\/td>\nYa\u015fam\u0131n ikinci y\u0131l\u0131nda; son dozdan en az 2 ay sonra<\/td>\n<\/tr>\n
12\u201323 ay<\/td>\nEn az 2 ay arayla 2 doz<\/td>\nBa\u015flang\u0131\u00e7 serisinin tamamlanmas\u0131ndan 12\u201323 ay sonra<\/td>\n<\/tr>\n
2\u201310 ya\u015f<\/td>\nEn az 1 ay arayla 2 doz<\/td>\nS\u00fcregelen risk ve resm\u00ee \u00f6nerilere g\u00f6re de\u011ferlendirilir<\/td>\n<\/tr>\n
11 ya\u015f ve \u00fczeri<\/td>\nEn az 1 ay arayla 2 doz<\/td>\nS\u00fcregelen risk ve resm\u00ee \u00f6nerilere g\u00f6re de\u011ferlendirilir<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n\n

Tablodaki aral\u0131klar en k\u0131sa s\u00fcrelerdir; ki\u015fisel randevu takvimi de\u011fildir. Yurt d\u0131\u015f\u0131nda ba\u015flanm\u0131\u015f serilerde \u00fclkeye \u00f6zg\u00fc \u00f6neriler farkl\u0131 olabilir. \u00d6nceki doz tarihi ve kullan\u0131lan \u00fcr\u00fcn do\u011frulanarak devam plan\u0131 olu\u015fturulur.<\/p>\n\n

<\/span>Bexsero Nas\u0131l Uygulan\u0131r?<\/span><\/h2>\n\n

Bexsero kas i\u00e7ine uygulan\u0131r. Enjeksiyon b\u00f6lgesi bebeklerde genellikle uyluk, daha b\u00fcy\u00fck \u00e7ocuklarda ve yeti\u015fkinlerde \u00fcst koldur. Her doz 0,5 ml\u2019dir. Uygulama sa\u011fl\u0131k personeli taraf\u0131ndan yap\u0131l\u0131r.[1]<\/p>\n\n

<\/span>Bexsero Ne Kadar Korur?<\/span><\/h2>\n\n

Bexsero, meningokok B hastal\u0131\u011f\u0131na kar\u015f\u0131 koruma sa\u011flamaya yard\u0131mc\u0131 olur. \u0130ngiltere\u2019deki \u00e7ocukluk a\u015f\u0131lama program\u0131nda MenB hastal\u0131\u011f\u0131nda belirgin azalma g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Bununla birlikte hi\u00e7bir a\u015f\u0131 t\u00fcm vakalar\u0131 \u00f6nleyemez; koruma t\u00fcm meningokok B su\u015flar\u0131n\u0131 kapsamayabilir.[3,4]<\/p>\n\n

Koruyuculuk \u00f6m\u00fcr boyu garanti de\u011fildir. MenB a\u015f\u0131lar\u0131ndan sonra koruyucu antikorlar zamanla azalabilir. Bu nedenle devam eden risk varsa ek doz gereksinimi ayr\u0131ca de\u011ferlendirilir.[4]<\/p>\n\n

<\/span>Bexsero ile Di\u011fer Menenjit A\u015f\u0131lar\u0131 Aras\u0131ndaki Fark Nedir?<\/span><\/h2>\n\n

Bexsero ile MenACWY a\u015f\u0131lar\u0131 (\u00f6rne\u011fin Nimenrix) farkl\u0131 meningokok gruplar\u0131n\u0131 hedefler. Daha \u00f6nce \u201cmenenjit a\u015f\u0131s\u0131\u201d yapt\u0131rm\u0131\u015f olmak, meningokok B\u2019ye kar\u015f\u0131 a\u015f\u0131lanm\u0131\u015f olmak anlam\u0131na gelmeyebilir. A\u015f\u0131 kart\u0131ndaki \u00fcr\u00fcn ad\u0131 bu ayr\u0131m i\u00e7in \u00f6nemlidir.[4]<\/p>\n\n

\n\n\n\n\n\n
A\u015f\u0131 t\u00fcr\u00fc<\/th>\nHedefledi\u011fi meningokok gruplar\u0131<\/th>\n<\/tr>\n<\/thead>\n
Bexsero \u2014 MenB a\u015f\u0131s\u0131<\/td>\nB grubu<\/td>\n<\/tr>\n
MenACWY a\u015f\u0131lar\u0131<\/td>\nA, C, W ve Y gruplar\u0131<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n\n

Bu a\u015f\u0131lar birbirinin yerine ge\u00e7mez.<\/strong> Ki\u015finin durumuna g\u00f6re her iki gruba y\u00f6nelik a\u015f\u0131lama da de\u011ferlendirilebilir. Bexsero ve Nimenrix gibi farkl\u0131 menenjit a\u015f\u0131lar\u0131n\u0131n ayn\u0131 g\u00fcn m\u00fc, ayr\u0131 randevularda m\u0131 yap\u0131laca\u011f\u0131 ya\u015fa ve g\u00fcncel \u00fcr\u00fcn bilgisine g\u00f6re hekim taraf\u0131ndan planlan\u0131r.[4]<\/p>\n\n

<\/span>Bexsero A\u015f\u0131s\u0131n\u0131n Yan Etkileri Nelerdir?<\/span><\/h2>\n\n

Bexsero sonras\u0131nda enjeksiyon yerinde a\u011fr\u0131, k\u0131zar\u0131kl\u0131k veya \u015fi\u015flik g\u00f6r\u00fclebilir. \u00c7ocuklarda ate\u015f, huzursuzluk, yorgunluk ve i\u015ftah azalmas\u0131 geli\u015febilir. \u00c7o\u011fu hafif reaksiyon bir veya iki g\u00fcn i\u00e7inde d\u00fczelir. Ate\u015f d\u00fc\u015f\u00fcr\u00fcc\u00fc gereksinimi ve kullan\u0131m \u015fekli, \u00f6zellikle bebeklerde sa\u011fl\u0131k ekibiyle planlanmal\u0131d\u0131r.[3]<\/p>\n\n

Ciddi alerjik reaksiyonlar \u00e7ok nadirdir. A\u015f\u0131 sonras\u0131nda nefes almada g\u00fc\u00e7l\u00fck, y\u00fcz veya bo\u011fazda \u015fi\u015fme ya da bayg\u0131nl\u0131k geli\u015firse acil yard\u0131m al\u0131nmal\u0131d\u0131r. Ate\u015fin uzamas\u0131 veya \u00e7ocu\u011fun genel durumunun k\u00f6t\u00fcle\u015fmesi de de\u011ferlendirme gerektirir.[3]<\/p>\n\n

<\/span>Bexsero \u00d6ncesinde Hangi Bilgiler Payla\u015f\u0131lmal\u0131?<\/span><\/h2>\n\n

Bexsero \u00f6ncesinde \u00f6nceki dozlara veya a\u015f\u0131 bile\u015fenlerine kar\u015f\u0131 ciddi alerji, mevcut ate\u015fli hastal\u0131k, kullan\u0131lan ila\u00e7lar ve gebelik ya da emzirme durumu sa\u011fl\u0131k ekibine bildirilmelidir. \u00d6nceki doza veya bile\u015fenlere ciddi alerji varsa a\u015f\u0131 uygulanmaz; y\u00fcksek ate\u015fli a\u011f\u0131r hastal\u0131kta uygulama ertelenebilir. Hafif so\u011fuk alg\u0131nl\u0131\u011f\u0131 ise tek ba\u015f\u0131na erteleme nedeni olmayabilir.[1,3]<\/p>\n\n

<\/span>\u0130stanbul\u2019da Bexsero A\u015f\u0131s\u0131 \u0130\u00e7in Randevu<\/span><\/h2>\n\n

\u0130stanbul\u2019da Bexsero a\u015f\u0131s\u0131n\u0131n nerede yap\u0131ld\u0131\u011f\u0131, randevu ve uygulama s\u00fcreci hakk\u0131nda bilgi almak i\u00e7in Dr. Soner D\u00fczg\u00fcner Klini\u011fi ile ileti\u015fime ge\u00e7ebilirsiniz. Randevu \u00f6ncesinde a\u015f\u0131lanacak ki\u015finin ya\u015f\u0131, \u00f6nceki a\u015f\u0131 kay\u0131tlar\u0131 ve tercih edilen tarih payla\u015f\u0131lmal\u0131d\u0131r. Uygunluk, g\u00fcncel stok ve \u00fccret bilgisi ekibimiz taraf\u0131ndan teyit edilir. Uygulanan doz, a\u015f\u0131 kart\u0131na veya uluslararas\u0131 a\u015f\u0131 sertifikas\u0131na i\u015flenebilir.<\/p>\n\n

Yurt d\u0131\u015f\u0131ndan gelecek ki\u015filerin a\u015f\u0131 kart\u0131n\u0131 ve \u0130stanbul\u2019da bulunacaklar\u0131 tarih aral\u0131\u011f\u0131n\u0131 \u00f6nceden iletmeleri planlamay\u0131 kolayla\u015ft\u0131r\u0131r. Seyahat s\u00fcresine g\u00f6re t\u00fcm dozlar\u0131n tek ziyarette tamamlanabilece\u011fi varsay\u0131lmamal\u0131d\u0131r.<\/p>\n\n

\u0130leti\u015fim ve randevu i\u00e7in +90 545 440 55 45<\/a><\/strong> numaras\u0131ndan ekibimize ula\u015fabilirsiniz.<\/p>\n\n

<\/span>Bexsero Hakk\u0131nda S\u0131k Sorulan Sorular<\/span><\/h2>\n\n

Bexsero hakk\u0131nda en s\u0131k sorulan sorular; mevcut a\u015f\u0131larla fark\u0131, dozlar\u0131n tamamlanmas\u0131, yan etkiler ve randevu \u00f6ncesi haz\u0131rl\u0131kla ilgilidir. Ki\u015fisel a\u015f\u0131 plan\u0131 i\u00e7in kay\u0131tlar\u0131n birlikte de\u011ferlendirilmesi gerekir.<\/p>\n\n

Menenjit B A\u015f\u0131s\u0131 Ne Zaman Yap\u0131l\u0131r?<\/h3>\n\n

Bexsero 2 ayl\u0131ktan itibaren uygulanabilir. \u0130lk dozun zaman\u0131 ve sonraki dozlar ya\u015fa g\u00f6re de\u011fi\u015fir; ayr\u0131nt\u0131lar yukar\u0131daki a\u015f\u0131 takvimi tablosunda yer al\u0131r. Ki\u015fiye uygun zamanlama, ya\u015f ve \u00f6nceki a\u015f\u0131 kay\u0131tlar\u0131na g\u00f6re belirlenir.[1,2]<\/p>\n\n

Bexsero Ate\u015f Yapar m\u0131?<\/h3>\n\n

Bexsero sonras\u0131nda, \u00f6zellikle bebeklerde ve \u00e7ocuklarda ate\u015f g\u00f6r\u00fclebilir. \u00c7o\u011fu hafif reaksiyon bir veya iki g\u00fcn i\u00e7inde d\u00fczelir. Ate\u015f d\u00fc\u015f\u00fcr\u00fcc\u00fc kullan\u0131m\u0131 sa\u011fl\u0131k ekibiyle planlanmal\u0131; ate\u015fin uzamas\u0131 veya genel durumun k\u00f6t\u00fcle\u015fmesi halinde de\u011ferlendirme yap\u0131lmal\u0131d\u0131r.[3]<\/p>\n\n

Bexsero A\u015f\u0131s\u0131 G\u00fcvenli mi?<\/h3>\n\n

Bexsero, T\u00fcrkiye\u2019de T\u0130TCK kullanma talimat\u0131 ve Avrupa\u2019da EMA \u00fcr\u00fcn bilgisi bulunan bir a\u015f\u0131d\u0131r. Yan etkilerin \u00e7o\u011fu hafiftir ve k\u0131sa s\u00fcrede ge\u00e7er; ciddi alerjik reaksiyonlar \u00e7ok nadirdir. Ki\u015fisel risk ve uygunluk, a\u015f\u0131 \u00f6ncesinde sa\u011fl\u0131k ekibiyle de\u011ferlendirilir.[1,2,3]<\/p>\n\n

Bexsero T\u00fcm Menenjit T\u00fcrlerinden Korur mu?<\/h3>\n\n

Hay\u0131r. Meningokok B\u2019yi hedefler; di\u011fer meningokok gruplar\u0131n\u0131n, ba\u015fka bakterilerin veya vir\u00fcslerin neden oldu\u011fu t\u00fcm menenjitlere kar\u015f\u0131 koruma sa\u011flamaz.[3,4]<\/p>\n\n

Daha \u00d6nce MenACWY A\u015f\u0131s\u0131 Oldum, Bexsero Gerekir mi?<\/h3>\n\n

MenACWY a\u015f\u0131s\u0131 B grubuna kar\u015f\u0131 koruma sa\u011flamaz. Bexsero gereksinimi ya\u015f\u0131n\u0131z ve risk durumunuz dikkate al\u0131narak ayr\u0131ca de\u011ferlendirilir.[4]<\/p>\n\n

\u0130lk Dozumu Ba\u015fka Bir \u00dclkede Yapt\u0131rd\u0131m, Devam Edebilir miyim?<\/h3>\n\n

Devam plan\u0131 i\u00e7in \u00f6nceki a\u015f\u0131n\u0131n ad\u0131, uygulama tarihi ve doz say\u0131s\u0131 incelenmelidir. A\u015f\u0131 kart\u0131n\u0131z\u0131n foto\u011fraf\u0131n\u0131 randevu \u00f6ncesinde payla\u015fabilirsiniz. Farkl\u0131 \u00fclkelerdeki programlar birebir ayn\u0131 olmayabilir.<\/p>\n\n

Bexsero A\u015f\u0131s\u0131 Fiyat\u0131 Ne Kadar?<\/h3>\n\n

G\u00fcncel tek doz \u00fccreti, toplam doz gereksinimi ve hizmet kapsam\u0131 i\u00e7in klini\u011fimizle ileti\u015fime ge\u00e7ebilirsiniz. Toplam maliyet, ki\u015fiye \u00f6nerilen a\u015f\u0131lama plan\u0131 netle\u015ftikten sonra a\u00e7\u0131klanabilir.<\/p>\n\n

<\/span>Yararlan\u0131lan Kaynaklar<\/span><\/h2>\n\n

Bu yaz\u0131n\u0131n t\u0131bbi i\u00e7eri\u011fi a\u015fa\u011f\u0131daki \u00fcr\u00fcn bilgileri ve resm\u00ee sa\u011fl\u0131k kaynaklar\u0131 kullan\u0131larak haz\u0131rlanm\u0131\u015ft\u0131r.<\/p>\n\n

    \n
  1. T\u00fcrkiye \u0130la\u00e7 ve T\u0131bbi Cihaz Kurumu \u2014 T\u0130TCK.<\/strong> Bexsero Kullanma Talimat\u0131 (prospekt\u00fcs).
    T\u0130TCK K\u00dcB\/KT veri taban\u0131<\/a><\/li>\n
  2. European Medicines Agency \u2014 EMA.<\/strong> Bexsero: EPAR \u2013 Product Information.
    EMA Bexsero \u00fcr\u00fcn bilgisi<\/a><\/li>\n
  3. National Health Service \u2014 NHS.<\/strong> MenB vaccine.
    NHS \u2014 \u00c7ocuklarda MenB a\u015f\u0131s\u0131<\/a><\/li>\n
  4. Centers for Disease Control and Prevention \u2014 CDC.<\/strong> Types of Meningococcal Vaccines.
    CDC \u2014 Meningokok a\u015f\u0131 t\u00fcrleri<\/a><\/li>\n<\/ol>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div><\/div>
    <\/div><\/div><\/div><\/div><\/div>
    \n\t
    \n\t\t
    \n\t\t\t
    Sizi Arayal\u0131m<\/span><\/div>\n\n\t\t<\/div>\n\t<\/div>
    \n\t\n\t\t<\/span>\n\t<\/span>\n<\/div>\n\t
    \n\t\t
    \n\t\t\t

    Dan\u0131\u015fmak istedi\u011finiz konularla ilgili h\u0131zl\u0131ca size ula\u015fal\u0131m.<\/span><\/p>\n\n\t\t<\/div>\n\t<\/div>

    \n\t\n\t\t<\/span>\n\t<\/span>\n<\/div>\n
    \n

    <\/p>